Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) and the cluster of differentiation36 (CD36) expression: a potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD)
Naunyn-Schmiedeberg's Archives of Pharmacology · 2025-07 · 398 (7) · 8567-8585
DOI: 10.1007/s00210-025-03789-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 17.01.2025. Verfasst von Dahshan Hassan Selim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11651, Cairo, Egypt. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, CD36 Antigens, Liraglutide, Dexamethasone. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Al-Azhar University.
Abstract (Originalsprache)
The clinical use of dexamethasone (DXM) is associated with the development of non-alcoholic fatty liver disease (NAFLD). However, the mechanisms by which DXM-induced NAFLD is still incompletely known. Therefore, the current study aims to test the hypothesis that DXM-induced NAFLD is mediated by dysregulation of key genes involved in lipid metabolism and liraglutide (LG) can ameliorate these effects. The histopathological and biochemical analysis assessed the effects of DXM and/or LG in liver tissue. The computational analysis was performed to detect the glucocorticoid response elements (GRE) in the promotor regions of FASN and CD36 genes. The effects of DXM and LG on the expression of FASN and CD36 were determined by real-time quantitative reverse transcription PCR (RT-qPCR), western blot (WB) and immunohistochemical (IHC) analyses. The NAFLD induced by high-fat diet (HFD) and DXM was manifested by increased levels of liver enzymes, deterioration of histological architecture of the liver tissue and accumulation of fat droplets. Computational analysis revealed that the promotor regions of FASN and CD36 harper several GRE. Most importantly, treatment with DXM decreased phosphorylated adenosine monophosphate-activated protein kinase (p-AMPK) levels, while LG upregulate it. In addition, treatment with DXM increased expression of FASN and CD36 , whereas LG ameliorated these effects in a dose-dependent manner. DXM-induced NAFLD is mediated by upregulation of FASN and CD36 expression which may be attributed to GRE. LG coupling with DXM mitigates this induction by downregulating FASN and CD36 levels and therefore mitigates the development of NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11651, Cairo, Egypt.
- Department of Pharmacy Practice, Faculty of Pharmacy, Sinai University-Kantara Branch, Ismailia City, 41636, Egypt.
- Department of Ophthalmology and Visual Science, Havener Eye Institute, The Ohio State University Wexner Medical Center, Columbus, OH, 43210, USA.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy (Boys), Al-Azhar University, Nasr City, 11651, Cairo, Egypt. Raedismail@azhar.edu.eg.
Förderung
- Al-Azhar University
Zitieren
APA
Selim, D. H., Mokhlis, H. A., Elsayed, A. M., Shatat, A. S., Salama, S. A., & Ismail, R. S. (2025). Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) and the cluster of differentiation36 (CD36) expression: a potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD). Naunyn-Schmiedeberg's Archives of Pharmacology, 398(7), 8567-8585. https://doi.org/10.1007/s00210-025-03789-6
Vancouver
Selim DH, Mokhlis HA, Elsayed AM, Shatat AS, Salama SA, Ismail RS. Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) and the cluster of differentiation36 (CD36) expression: a potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD). Naunyn-Schmiedeberg's Archives of Pharmacology. 2025;398(7):8567-8585. doi:10.1007/s00210-025-03789-6
BibTeX
@article{Selim2025,
author = {Selim, Dahshan Hassan and Mokhlis, Hamada Ahmed and Elsayed, Abdelrahman M and Shatat, Abdel-Aziz S and Salama, Salama Abdou and Ismail, Raed Shahat},
title = {Liraglutide mitigates dexamethasone-induced fatty acid synthase (FASN) and the cluster of differentiation36 (CD36) expression: a potential treatment for glucocorticoid-induced non-alcoholic fatty liver disease (NAFLD)},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2025},
volume = {398},
number = {7},
pages = {8567--8585},
doi = {10.1007/s00210-025-03789-6}
}
EUVIMED